Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase Cα-mediated nuclear factor-κB activation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 1, 2007, Pages 219-225

  Kawakami, Akio ^a,c   Aikawa, Masanori ^b   Nitta, Noriko ^c   Yoshida, Masayuki ^c   Libby, Peter ^b   Sacks, Frank M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Adhesion molecules; Apolipoproteins; Atherosclerosis; Leukocytes; Signal transduction

Indexed keywords

APOLIPOPROTEIN C3; BETA1 INTEGRIN; ENZYME INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PERTUSSIS TOXIN; PHOSPHOLIPASE C; PROTEIN KINASE C ALPHA; SN 50; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; BRIDGED COMPOUND; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; PHOSPHODIESTERASE INHIBITOR; THIOKETONE; TRICYCLODECANE 9 YL XANTHOGENATE; TRICYCLODECANE-9-YL-XANTHOGENATE;

ARTICLE; ATHEROGENESIS; CELL ADHESION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL LINE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANTIGENS, CD29; APOLIPOPROTEIN C-III; BRIDGED COMPOUNDS; CELL ADHESION; CELL LINE; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; MONOCYTES; NF-KAPPA B; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE C-ALPHA; THIONES;

EID: 33847013084     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000249620.68705.0d     Document Type: Article

References (24)

1. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
2. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, Girelli D, Friso S, Pignatti PF, Corrocher R. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res. 2003;44:2374-2381.
3. Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, Assmann G. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168:81-89.
4. Lee SJ, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol. 2003;23:853-858.
5. Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75:384-390.
6. Clavey V, Lestavel-Delattre S, Copin C, Bard JM, Fruchart JC. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995;15:963-971.
7. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113:691-700.
8. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859-866.
9. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell Signal. 1998;10:529-542.
10. Rask-Madsen C, King GL. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:487-496.
11. Yoshida M, Sawada T, Ishii H, Gerszten RE, Rosenzweig A, Gimbrone MA, Jr., Yasukochi Y, Numano F. HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001;21:1165-1171.
12. Lu Y, Morley P, Durkin JP. Signalling events mediating the activation of protein kinase C by interleukin-2 in cytotoxic T cells. Cell Signal. 1999;11:275-285.
13. Melien O, Sandnes D, Johansen EJ, Christoffersen T. Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: Evidence suggesting a stimulatory role of Gi proteins at a level distal to receptor coupling. J Cell Physiol. 2000;184:27-36.
14. Wang JH, Manning BJ, Wu QD, Blankson S, Bouchier-Hayes D, Redmond HP. Endotoxin/lipopolysaccharide activates NF-{kappa}B and enhances tumor cell adhesion and invasion through a {beta}1 integrindependent mechanism. J Immunol. 2003;170:795-804.
15. Ghosh S, Baltimore D. Activation in vitro of NF-{kappa}B by phosphorylation of its inhibitor I{kappa}B. Nature. 1990;344:678-682.
16. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-{kappa}B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270:14255-14258.
17. Wheeler-Jones CPD. Cell signalling in the cardiovascular system: an overview. Heart. 2005;91:1366-1374.
18. Zhao D, Letterman J, Schreiber BM. beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell proliferation. J Biol Chem. 2001;276:30579-30588.
19. Kawakami A, Tanaka A, Chiba T, Nakajima K, Shimokado K, Yoshida M. Remnant lipoprotein-induced smooth muscle cell proliferation involves epidermal growth factor receptor transactivation. Circulation. 2003;108:2679-2688.
20. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C, Remuzzi G. Leukocyte-endothelial Interaction is augmented by high glucose concentrations and hyperglycemia in a NF-{kappa}B-dependent fashion. J Clin Invest. 1998;101:1905-1915.
21. Chen CC, Chou CY, Sun YT, Huang WC. Tumor necrosis factor {alpha}-induced activation of downstream NF-{kappa}B site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion: Involvement of PKC[alpha], tyrosine kinase, and IKK2, but not MAPKs, pathway. Cell Signal. 2001;13:543-553.
22. Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH. Protein kinase C{alpha}-mediated chemotaxis of neutrophils requires NF-{kappa}B activity but is independent of TNF{alpha} signaling in mouse skin in vivo. J Immunol. 2005;174:1686-1692.
23. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114:681-687.
24. Monaco C, Paleolog E. Nuclear factor [kappa]B: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671-682.